Research Center

Hospital Agamenon Magalhaes

Cardiovascular Diseases

Heart Failure

COVID-19

Myocardial Infarction

Atherosclerosis

Infarction

ST Elevation Myocardial Infarction

PF-07321332

Ritonavir

Empagliflozin

Bococizumab

Ticagrelor

Heparin

Olpasiran

EMPagliflozin

Pfizer

Boehringer Ingelheim

Amgen

University of Manitoba

Hospital do Coracao

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein(a).

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

Hospital Agamenon Magalhaes | Research Center

Site insights

Work at this site?

Active trials

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

Trial sponsors